Codagenix completed round B financing of US $20 million

Recently, codagenix announced the completion of round B financing of US $20 million to support the further clinical development of its live attenuated vaccine against respiratory syncytial virus (RSV) infection in the elderly, influenza vaccine, and oncolytic therapy for triple negative breast cancer (TNBC) patients Codagenix is a synthetic biology company in the clinical stage It uses software to recode the genome of the virus and build live attenuated vaccine or virus to prevent virus infection or treat solid tumor The recoded candidate vaccine developed by codagenix can induce a strong immune response to most viral antigens after matching with the target viral antigens The company's flexible development platform also enables them to turn viruses into potential oncolytic immunotherapies Recently, cloudcath announced the completion of 12 million US dollars a round of financing to support the commercial development of its first treatment monitoring platform and further develop other applications based on remote monitoring technology Cloudcath's first product is a medical device designed for end-stage renal disease patients undergoing peritoneal dialysis at home The device can be placed around the blood transfusion tube of the dialysis system and connected with the monitoring software It can not only analyze the drainage fluid, but also detect the deviation of the characteristics of the drainage fluid using a special algorithm The device uses a built-in LTE communication module, which can send the notification of complications to the doctor of the patient These alerts then quickly appear on their doctor's patient management portal.